SRRM2: A 300 kDa Nuclear Matrix Antigen as a Drug Target or Biomarker

Target Name: SRRM2

NCBI ID: G23524

SRRM2

SRRM2: A 300 kDa Nuclear Matrix Antigen as a Drug Target or Biomarker

SRRM2 (sinonin-related receptor subfamily 2) is a 300 kDa nuclear matrix antigen that has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique molecular features and subcellular localization in nuclear matrix have made it an attractive target for researchers to investigate, and potential therapeutic approaches.

TheSRRM2 is a member of the subfamily of nuclear matrix antigens (SMAs), which are a type of transmembrane protein that are expressed in various cell types and play a crucial role in cell-cell adhesion, migration, and invasion. SMAs are characterized by the presence of a unique nucleotide-rich region (NRE), which is involved in cell signaling and is thought to play a role in the regulation of cellular processes such as cell growth, differentiation, and apoptosis.

One of the unique features of SRRM2 is its subcellular localization in the nuclear matrix. The nuclear matrix is a protein complex that occupies the space between the nuclear membrane and the cytoplasm, and it is composed of various proteins that help to maintain the structural integrity of the nuclear envelope and provide support for the nuclear chromosomes.SRRM2 is one of the proteins that is specifically expressed in the nuclear matrix, and its localization to this subcellular region suggests that it plays an important role in the regulation of nuclear processes.

The potential drug target or biomarker properties of SRRM2 are due to its unique expression pattern and the various functions that it is involved in. One of the main reasons for its potential as a drug target is its involvement in cellular signaling pathways. For example, SRRM2 has been shown to be involved in the regulation of cell growth, differentiation, and apoptosis, and it has been shown to play a role in the development of various diseases, including cancer. Additionally, its subcellular localization in the nuclear matrix suggests that it may be involved in the regulation of nuclear processes that are critical for the survival and growth of cells.

Another potential reason for the interest in SRRM2 as a drug target is its expression in various disease-related tissues and its potential to serve as a biomarker for disease diagnosis and monitoring. For example, SRRM2 has been shown to be expressed in various cancer tissues, including breast cancer, lung cancer, and colorectal cancer, and it has been used as a marker for the diagnosis and evaluation of these diseases. Additionally, its subcellular localization in the nuclear matrix may make it a useful biomarker for the monitoring of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

The identification of SRRM2 as a potential drug target or biomarker has led to a significant amount of research, both in the scientific literature and in the development of potential therapeutic approaches. One of the main approaches that have been explored is the use of small molecules to inhibit the activity of SRRM2 and its downstream signaling pathways. This has led to the development of a variety of potential therapeutic compounds, including inhibitors of tyrosine kinase activity, inhibitors of NF-kappa-B signaling, and inhibitors of microtubule dynamics. Additionally, cell-based assays have been used to evaluate the efficacy of these compounds and to identify potential candidates for further development.

Another promising approach to the development of SRRM2 as a drug target is its use as a cancer vaccine. Cancer vaccines are a type of vaccine that are designed to stimulate an immune response against cancer cells, with the goal of providing a safe and effective cancer treatment.SR

Protein Name: Serine/arginine Repetitive Matrix 2

Functions: Required for pre-mRNA splicing as component of the spliceosome. As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable)

The "SRRM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRRM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets